Investing A La Carte: Making Separate Bets on Discovery and Development to Boost Near-Term Returns
This article was originally published in Start Up
As executives and investors scramble to find business models that more closely link investment and return, a handful of technology firms have alit on variations of a capital-efficient strategy: let someone else do the development dirty work.
You may also be interested in...
A secondary offering by the privately held antibody discovery play has valued the company at more than a billion dollars and allowed its venture investors to cash in some or all of their positions. Meanwhile, Adimab continues to announce new partnerships including a monoclonal and bispecific antibody discovery pact with Sanofi.
Antibody platform play Ablexis has successfully built its technology, fulfilled a commitment to its pharmaceutical partners, triumphed in a lawsuit brought by one of biotech’s big boys, and lined the pockets of its investors. Surprisingly, it has no imitators.
Alzheimer’s-focused Alector combines its scientific founders’ biological insight with antibody discovery technology from Adimab, allowing Adimab’s backers and executives to pursue multiple but distinct bets on the success of their platform.